Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies.
Blood Cancer Discov
; 4(3): 172-175, 2023 05 01.
Article
en En
| MEDLINE
| ID: mdl-37078891
ABSTRACT
SUMMARY:
In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Hematológicas
/
COVID-19
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Revista:
Blood Cancer Discov
Año:
2023
Tipo del documento:
Article
País de afiliación:
Francia